February 15, 1995Circulation
Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis
Why the study?
Does a PAI-1-neutralizing monoclonal antibody improve thrombolysis and prevent reocclusion in experimental thrombosis models?
Population
Rabbit jugular vein thrombosis model and canine model of coronary artery thrombosis superimposed on a…
Comparison
PAI-1-neutralizing monoclonal antibody 1 mg/kg… vs Nonspecific monoclonal antibody or rTPA alone.
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for anti-PAI-1 adjuncts to thrombolysis; leaves open translation to human coronary syndromes.
Structured PICO
Does a PAI-1-neutralizing monoclonal antibody improve thrombolysis and prevent reocclusion in experimental thrombosis models?
P
Population
Rabbit jugular vein thrombosis model and canine model of coronary artery thrombosis superimposed on a high-grade stenosis and endothelial damage (n=8 dogs in rTPA group).
I
Intervention
PAI-1-neutralizing monoclonal antibody (CLB-2C8) 1 mg/kg intravenous, alone or in combination with recombinant tissue-type plasminogen activator (rTPA).
C
Comparator
Nonspecific monoclonal antibody (control) or rTPA alone.
O
Outcome
Thrombolysis, thrombus growth, time to reperfusion, and time to reocclusion.surrogate
A PAI-1-neutralizing monoclonal antibody enhances endogenous thrombolysis, inhibits thrombus growth, and facilitates rTPA-induced reperfusion while delaying reocclusion in animal models of thrombosis.
Cite This Study
Biemond et al. (1995) studied this question.